AP3283A - N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors - Google Patents

N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Info

Publication number
AP3283A
AP3283A AP2012006269A AP2012006269A AP3283A AP 3283 A AP3283 A AP 3283A AP 2012006269 A AP2012006269 A AP 2012006269A AP 2012006269 A AP2012006269 A AP 2012006269A AP 3283 A AP3283 A AP 3283A
Authority
AP
ARIPO
Prior art keywords
coa carboxylase
carboxylase inhibitors
pyrazolospiroketone
acetyl
pyrazolospiroketone acetyl
Prior art date
Application number
AP2012006269A
Other languages
English (en)
Other versions
AP2012006269A0 (en
Inventor
Scott William Bagley
David Andrew Griffith
Daniel Wei-Shung Kung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2012006269A0 publication Critical patent/AP2012006269A0/xx
Application granted granted Critical
Publication of AP3283A publication Critical patent/AP3283A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2012006269A 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors AP3283A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Publications (2)

Publication Number Publication Date
AP2012006269A0 AP2012006269A0 (en) 2012-06-30
AP3283A true AP3283A (en) 2015-05-31

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006269A AP3283A (en) 2009-11-10 2010-10-29 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Country Status (39)

Country Link
US (4) US8288405B2 (xx)
EP (3) EP2947082A1 (xx)
JP (1) JP5114610B1 (xx)
KR (2) KR101550557B1 (xx)
CN (1) CN102695708B (xx)
AP (1) AP3283A (xx)
AR (1) AR078944A1 (xx)
AU (1) AU2010317501B2 (xx)
BR (1) BR112012011072A2 (xx)
CA (1) CA2778886C (xx)
CL (1) CL2012000999A1 (xx)
CO (1) CO6541569A2 (xx)
CR (1) CR20120190A (xx)
CU (1) CU24077B1 (xx)
DK (1) DK2499139T3 (xx)
DO (1) DOP2012000128A (xx)
EA (1) EA020153B1 (xx)
EC (1) ECSP12011880A (xx)
ES (1) ES2444543T3 (xx)
GE (1) GEP20146169B (xx)
HN (1) HN2012000973A (xx)
HR (1) HRP20140025T1 (xx)
IL (1) IL219373A (xx)
MA (1) MA33734B1 (xx)
MX (1) MX2012005429A (xx)
NI (1) NI201200089A (xx)
NZ (1) NZ599815A (xx)
PE (1) PE20121469A1 (xx)
PH (1) PH12012500903A1 (xx)
PL (1) PL2499139T3 (xx)
PT (1) PT2499139E (xx)
RS (1) RS53156B (xx)
SI (1) SI2499139T1 (xx)
TN (1) TN2012000192A1 (xx)
TW (1) TWI394756B (xx)
UA (1) UA102336C2 (xx)
UY (1) UY33020A (xx)
WO (1) WO2011058474A1 (xx)
ZA (1) ZA201204231B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011058474A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
HRP20161178T1 (hr) * 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
HK1217448A1 (zh) 2013-09-12 2017-01-13 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112017005128A2 (pt) 2014-09-16 2018-07-31 Celgene Quanticel Res Inc inibidores de histona desmetilase
MX2017003463A (es) * 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
CN107002262B (zh) 2014-11-10 2019-10-29 国立大学法人横浜国立大学 氧气发生用阳极
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds
FI3713942T3 (fi) 2017-11-21 2023-05-04 Pfizer 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
US12521375B2 (en) 2020-05-21 2026-01-13 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
AU2023316863A1 (en) * 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
WO2025133948A1 (en) * 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (en) * 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2008065508A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
WO2008088689A1 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
UA84208C2 (xx) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. ТЕТРААЗАБЕНЗО$е]АЗУЛЕНОВІ ПОХІДНІ ТА ЇХ АНАЛОГИ$ТЕТРААЗАБЕНЗО$е]АЗУЛЕНОВЫЕ ПРОИЗВОДНЫЕ И ИХ АНАЛОГИ
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
US8110570B2 (en) * 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011058474A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2499140A1 (en) 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011809A1 (en) * 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
EP1911753A1 (en) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2008065508A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
WO2008088689A1 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Substituted spirochromanone derivatives as acc inhibitors
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2008125945A2 (en) * 2007-04-12 2008-10-23 Pfizer Inc. 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors

Also Published As

Publication number Publication date
CO6541569A2 (es) 2012-10-16
GEP20146169B (en) 2014-09-25
HN2012000973A (es) 2015-03-02
CU24077B1 (es) 2015-03-30
DOP2012000128A (es) 2012-08-31
JP5114610B1 (ja) 2013-01-09
HK1173724A1 (en) 2013-05-24
CR20120190A (es) 2012-05-24
BR112012011072A2 (pt) 2017-06-20
UA102336C2 (xx) 2013-06-25
US8288405B2 (en) 2012-10-16
EP2676958A1 (en) 2013-12-25
MX2012005429A (es) 2012-06-19
KR101478517B1 (ko) 2015-01-02
TW201127838A (en) 2011-08-16
IL219373A0 (en) 2012-06-28
TWI394756B (zh) 2013-05-01
AP2012006269A0 (en) 2012-06-30
EP2499139A1 (en) 2012-09-19
EA201290191A1 (ru) 2012-12-28
HRP20140025T1 (hr) 2014-02-14
MA33734B1 (fr) 2012-11-01
US20130296319A1 (en) 2013-11-07
DK2499139T3 (da) 2014-01-27
EP2499139B1 (en) 2013-12-11
PE20121469A1 (es) 2012-11-01
AU2010317501A1 (en) 2012-05-17
ECSP12011880A (es) 2012-07-31
CU20120071A7 (es) 2013-05-31
IL219373A (en) 2014-04-30
US20140288111A1 (en) 2014-09-25
US8507681B2 (en) 2013-08-13
KR101550557B1 (ko) 2015-09-04
SI2499139T1 (sl) 2014-01-31
US20110111046A1 (en) 2011-05-12
US20130030181A1 (en) 2013-01-31
CA2778886C (en) 2014-01-07
CN102695708A (zh) 2012-09-26
RS53156B (sr) 2014-06-30
EA020153B1 (ru) 2014-09-30
EP2947082A1 (en) 2015-11-25
AU2010317501B2 (en) 2013-06-06
KR20120099460A (ko) 2012-09-10
CA2778886A1 (en) 2011-05-19
ZA201204231B (en) 2013-02-27
EP2676958B1 (en) 2015-07-01
ES2444543T3 (es) 2014-02-25
WO2011058474A8 (en) 2012-04-26
NZ599815A (en) 2013-04-26
PT2499139E (pt) 2014-02-10
PL2499139T3 (pl) 2014-04-30
NI201200089A (es) 2012-08-20
US9139587B2 (en) 2015-09-22
US8802690B2 (en) 2014-08-12
WO2011058474A1 (en) 2011-05-19
JP2013510192A (ja) 2013-03-21
TN2012000192A1 (fr) 2013-12-12
UY33020A (es) 2011-06-30
AR078944A1 (es) 2011-12-14
KR20140034919A (ko) 2014-03-20
CN102695708B (zh) 2014-10-15
PH12012500903A1 (en) 2014-09-24
CL2012000999A1 (es) 2012-07-20

Similar Documents

Publication Publication Date Title
AP3283A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
ZA201303882B (en) N1/n2-lactam acetyl-coa carboxylase inhibitors
GB2497438B (en) Level
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
IL198779A0 (en) Spiroketone acetyl-coa carboxylase inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
AP3499A (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
EP2443235A4 (en) ß-glucosidase VARIANTS
GB201009731D0 (en) Kinase inhibitors
GB0916010D0 (en) JMJD2 demethylase inhibitors
GB0914726D0 (en) Kinase inhibitors
GB201104990D0 (en) Screw-fix level
GB0903650D0 (en) Glyoalase inhibitors
GB0902661D0 (en) Inhibitors
GB0915927D0 (en) Novel inhibitors
GB201018597D0 (en) Inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors